GSK’s industry-leading respiratory research and scientific innovation showcased at ATS conference

16 May 2018 GlaxoSmithKline plc (GSK) will present extensive data from across its respiratory portfolio, pipeline and early phase research programmes at the American Thoracic Society (ATS) conference in San Diego, USA, 19-23 May 2018. Data presented in 61 abstracts

Simon Dingemans, Chief Financial Officer, to retire from GSK

09 May 2018 GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Simon Dingemans, Chief Financial Officer (CFO), GSK, has informed the Board of his intention to retire from the Company and to step down from the Board in May 2019. The

Once-daily Trelegy Ellipta gains expanded indication in the US for the treatment of patients with COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), which means this medicine can now be used by US

Landmark IMPACT study published in NEJM shows significant benefits of Trelegy Ellipta for patients with COPD

Once-daily single inhaler triple therapy superior to Relvar/Breo Ellipta and Anoro Ellipta across multiple endpoints including exacerbations, lung function and quality of life. GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the publication in the New England

GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics

Agreement strengthens Orchard’s position as a global leader in gene therapy for rare diseases. GSK takes 19.9% equity stake in Orchard and seat on board.  Issued: London, UK GSK and Orchard Therapeutics today announced a strategic agreement, under which GSK will

GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business

Agreement with Novartis to buyout Novartis’ 36.5% stake in the Consumer Healthcare Joint Venture for $13 billion (£9.2 billion)  Proposed transaction addresses one of the Group’s stated key capital allocation priorities, supporting efforts to improve performance and capital planning for